Tumor Immune Microenvironment and Its Regulatory Mechanism

Authors

  • Yue Yuan

DOI:

https://doi.org/10.62051/gbm4q645

Keywords:

Tumor immune microenvironment; gastric cancer; PD-1/PD-L1.

Abstract

Gastric cancer (GC) is a highly heterogeneous tumor, and TME plays a key role in tumorigenesis and progression. TME is composed of immune cells, CAF and ECM, which regulate the growth, invasion and metastasis of GC through complex interactions. Immune escape mechanisms, such as the activation of the PD-1/PD-L1 pathway, weaken the body's anti-tumor immune response and lead to further proliferation of tumor cells. In addition, high density of immunosuppressive cells and active CAF are strongly associated with poor prognosis in patients with GC. In recent years, targeted therapeutic strategies for TME, such as immune checkpoint inhibitors (ICIs), CAF inhibitors, and ECM remodeling modulators, have shown potential therapeutic effects and become a new way to improve the survival rate of GC patients. However, due to the complexity and heterogeneity of TME, future studies still need to further explore the specific mechanism of action of TME in different stages of GC, and develop more accurate personalized treatment plans. Multidisciplinary combined treatment strategies are expected to play an important role in improving the prognosis of patients with GC.

Downloads

Download data is not yet available.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2021, 71(3): 209-249.

[2] Mou P, Ge Q, Sheng R, et al. Research progress on the immune microenvironment and immunotherapy in gastric cancer. Frontiers in Immunology, 2023, 14: 1291117.

[3] Pradhan R, Kundu A, Kundu CN. The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth. Critical Reviews in Oncology/Hematology, 2024: 104311.

[4] Wang N, Wang S, Wang X, Zheng Y, Yang B, Zhang J, Pan B, Gao J, Wang Z. Research trends in pharmacological modulation of tumor-associated macrophages. Clinical and Translational Medicine, 2021, 11(1): e288.

[5] Yi M, Niu M, Xu L, et al. Regulation of PD-L1 expression in the tumor microenvironment. Journal of Hematology & Oncology, 2021, 14: 10.

[6] Zhang M, Zhong J, Song Z, et al. Regulatory mechanisms and potential therapeutic targets in precancerous lesions of gastric cancer: A comprehensive review. Biomedicine & Pharmacotherapy, 2024, 177: 117068.

[7] Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6(1): 72.

[8] De Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 2023, 41(3): 374-403.

Downloads

Published

24-12-2024

How to Cite

Yuan, Y. (2024). Tumor Immune Microenvironment and Its Regulatory Mechanism . Transactions on Materials, Biotechnology and Life Sciences, 7, 544-549. https://doi.org/10.62051/gbm4q645